🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

AstraZeneca starts trial of COVID-19 antibody treatment

Published 25/08/2020, 07:28
© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York
LLY
-
AZN
-
REGN
-

By Pushkala Aripaka and Aakash B

(Reuters) - British drugmaker AstraZeneca (L:AZN) has begun testing an antibody-based cocktail for the prevention and treatment of COVID-19, adding to recent signs of progress on possible medical solutions to the disease caused by the novel coronavirus.

The London-listed firm, already among the leading players in the global race to develop a successful vaccine, said the study would evaluate if AZD7442, a combination of two monoclonal antibodies (mAbs), was safe and tolerable in up to 48 healthy participants between the ages of 18 and 55 years.

If the UK-based early-stage trial, which has dosed its participants, shows AZD7442 is safe, AstraZeneca said it would proceed to test it as both a preventative treatment for COVID-19 and a medicine for patients who have it, in larger, mid-to-late-stage studies.

AstraZeneca shares were up about 1% at 87 pounds ($114) in early trading.

Development of mAbs to target the virus, an approach already being tested by Regeneron (O:REGN), ELi Lilly (N:LLY), Roche (S:ROG) and Molecular Partners (S:MOLN), has been endorsed by leading scientists.

mAbs mimic natural antibodies generated in the body to fight off infection and can be synthesised in the laboratory to treat diseases in patients. Current uses include treatment of some types of cancers.

U.S. infectious diseases expert Anthony Fauci has called them "almost a sure bet" against COVID-19, and AstraZeneca in June received $23.7 million in funding from U.S. government agencies to advance development of antibody-based treatments for COVID-19.

"This combination of antibodies, coupled to our proprietary half-life extension technology, has the potential to improve both the effectiveness and durability of use in addition to reducing the likelihood of viral resistance," said Astra's executive vice president of biopharmaceuticals R&D Mene Pangalos.

Though vaccines are at the heart of the long-term fight against the pandemic, alternative treatments are also being advanced, and the United States on Sunday authorized use of recovered COVID-19 patients' plasma to treat those who are ill.

© Reuters. FILE PHOTO: AstraZeneca's head of innovative medicines Mene Pangalos leaves after appearing at a parliamentary business and enterprise committee hearing at Portcullis House in London

The Financial Times reported at the weekend that President Donald Trump's administration was considering a fast-tracked approval of AstraZeneca's COVID-19 vaccine before November's elections.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.